Scottish Medicines Consortium (SMC)
Minutes of the SMC Meeting
held on Tuesday 04 March 2014
Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP
Present:
Observers:
In Attendance:
Apologies:
Professor Angela Timoney (Chair)
Ms Sandra Auld
Dr Jennifer Burns
Mrs Helen Cadden
Mrs Alison Campbell
Mr Ian Crichton
Dr Dominic Culligan
Dr Peter Currie
Mr John Dally
Dr Arthur Doyle
Dr Jonathan Fox
Dr John Gemmill
Dr Barclay Goudie
Mr Alan Gray
Dr Caroline Hind
Dr Alan MacDonald
Dr Frances Macdonald
Mrs Margo McGurk
Dr Michael McMahon
Professor Simon Maxwell
Professor Rose Marie Parr
Dr Robert Peel
Dr Berkeley Philips
Mrs Maggie Carey
Ms Kathryn Fergusson
Ms Irene Fazakerley
Dr Nirosha Gunatillake
Mr Kevin Jameson
Ms Sasha McKaig
Ms Kate Morgan
Ms Sue Perkins
Mrs Corinne Booth
Ms Ailsa Brown
Mr Stephen Ferguson
Dr Jan Jones
Mrs Anne Lee
Mr Kieran McQuaid
Ms Aileen Muir
Ms Rosie Murray
Dr Brian Robson
Mrs Maureen Stark
Mr James Stewart
Dr Andrew Walker
Dr Keith Brown
Mr Robert Calderwood
Professor David Cameron
Dr Sara Davies
Mrs Susan Downie
Dr Gordon Forrest
Dr Jacqui Howes
Mrs Kirsty Macfarlane
Dr James McLay
Dr Philip McMenemy
Dr Paul McNamee
Ms Veronica Moffat
Mrs Emma Riches
Professor Colin Suckling
Mrs Catherine Tait
Dr Sarah Taylor
Professor Matthew Walters
SMC Meetings/SMC Minutes – 04 March 2014
Page 1 of 11
Scottish Medicines Consortium (SMC)
1.
Welcome and Apologies for Absence
1.1
The Chairman welcomed members to the meeting and apologies for absence were noted.
1.2
Welcome to new SMC member and staff member:
• Mr James Stewart, who has been formally appointed as Public Involvement Officer for
the Scottish Medicines Consortium (SMC).
1.3
Welcome to the following observers:
1.4
•
Mrs Maggie Carey, recently appointed administrator for SMC.
•
Ms Irene Fazakerley, Scottish Government Health Directorate.
•
Dr Nirosha Gunatillake, a senior nephrology trainee working in NHS GG &C.
•
Mr Kevin Jameson, member of the New Drug Committee (NDC) and the SMC User
Group (UGF) representing the pharmaceutical industry (ABPI).
•
Ms Sasha McKaig, a health economist from NHS Ayrshire and Arran.
•
Ms Kate Morgan, Policy and Campaigns, Myeloma
•
Ms Sue Perkins, Head of Services, Myeloma UK
Welcome to New Observers - Patient Interest Groups:
Over the past 8 months the Scottish Medicines Consortium has been piloting summaries of
the Patient Interest Group submissions to SMC, with the intention of including these in the
detailed advice documents (DADs) for publication on our website in order to reflect the patient
voice. This pilot has been successful and we now propose to include a summary of the
patient interest group submission(s) in a separate section within the DAD. We have also
invited the groups to observe the meeting today.
1.5
Thank You and Goodbye to:
The following SMC members who have completed their extended terms of membership. The
Chairman thanked them for their support over the years and wished them well:
1.6
•
In her absence to Dr Sarah Taylor, Director of Public Health, NHS Shetland.
•
In his absence, Dr Keith Brown, Consultant Psychiatrist, NHS Forth Valley.
•
Dr Barclay Goudie, General Practitioner, NHS Tayside, who has been a valued
member of SMC since its inception.
Presentation SMC meetings being held in Public
Mr Keiran McQuaid, SMC Operations manager presented information on SMC meetings
being held in Public.
SMC Meetings/SMC Minutes – 04 March 2014
Page 2 of 11
Scottish Medicines Consortium (SMC)
Following the outcome of the Scottish Government’s request to review access to new
medicines, SMC will meet in public so that members of the public, patients, patient group
representatives, other health professionals and members of the pharmaceutical industry, can
attend to observe the appraisal process.
SMC is developing a process for meetings in public by providing training for SMC members
and considering and address information needs of members of the public.
The SMC committee meetings will be held in public from May 2014.
2.
Declarations of Interest
2.1
The Chairman reminded members to declare interests in the products to be discussed and
the comparator drugs as noted on the assessment reports.
3.
Minutes of the Previous Meeting (04 February 2014)
3.1
The minutes of the SMC meeting held on 04 February 2014, were accepted as an accurate
record of the meeting.
4
Matters Arising
Full Submissions
4.1
ceftobiprole (as medocaril sodium) 500mg powder for concentrate for solution for infusion
(Zevtera®) SMC No. (943/14) Basilea Pharmaceutica International Ltd.
4.1.1
The SMC advice for ceftobiprole (as medocaril sodium) (Zevtera®), for treatment of adults
with: Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP);
Community-acquired pneumonia (CAP), has been withheld pending confirmation of product
availability.
4.2
lenalidomide 2.5mg, 5mg, and , 10mg, hard capsules (Revlimid®) SMC No. (942/14)
Celgene Ltd
4.2.1
The SMC advice for lenalidomide (Revlimid®), for the treatment of patients with transfusiondependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated
with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are
insufficient or inadequate, will be published on the website on Monday 10 March 2014.
4.3
ustekinumab 45mg solution for injection in pre-filled syringe (Stelara®) SMC No. (944/14)
Janssen-Cilag Ltd
4.3.1
The SMC advice for ustekinumab (Stelara®), alone or in combination with methotrexate, for
the treatment of active psoriatic arthritis in adult patients when the response to previous nonbiological disease-modifying anti-rheumatic drug therapy has been inadequate, will be
published on the website on Monday 10 March 2014.
SMC Meetings/SMC Minutes – 04 March 2014
Page 3 of 11
Scottish Medicines Consortium (SMC)
Resubmissions
4.4
aflibercept 25mg/mL concentrate for solution for infusion (Zaltrap®) SMC No. (878/13)
Sanofi
4.4.1
The SMC advice for aflibercept (Zaltrap®), in combination with irinotecan/5-fluorouracil/folinic
acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal
cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen,
will be published on the website on Monday 10 March 2014.
4.5
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga®) SMC No. (799/12)
Bristol-Myers Squibb / AstraZeneca
4.5.1
The SMC advice for dapagliflozin (Forxiga®), for use in adults aged 18 years and older with
type 2 diabetes mellitus to improve glycaemic control in combination with other glucoselowering medicinal products including insulin, when these, together with diet and exercise, do
not provide adequate glycaemic control, will be published on the website on Monday 10
March 2014.
4.6
insulin degludec (Tresiba®) 100units/mL solution for injection in pre-filled pen or cartridge and
200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk
4.6.1
The SMC advice for insulin degludec (Tresiba®), for treatment of diabetes mellitus in adults,
will be published on the website on Monday 10 March 2014.
Abbreviated Submissions
4.7
solifenacin succinate plus tamsulosin hydrochloride 6mg / 0.4mg modified release tablet
(Vesomni®) (No: 945/14) Astellas Pharma Ltd
4.7.1
The SMC advice for solifenacin succinate plus tamsulosin hydrochloride (Vesomni®), for the
treatment of moderate to severe storage symptoms (urgency, increased micturition
frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who
are not adequately responding to treatment with monotherapy, will be published on the
website on Monday 10 March 2014.
4.8
darunavir 400mg, 800mg film-coated tablets and oral suspension 100mg/mL (Prezista®)
(No: 948/14) Janssen-Cilag Ltd
4.8.1
The SMC advice for darunavir (Prezista®), co-administered with low dose ritonavir in
combination with other antiretroviral medicinal products for the treatment of human
immunodeficiency virus (HIV-1) infection in paediatric patients 12 to 17 years of age and at
least 40kg body weight who are: antiretroviral therapy (ART) naïve; or, ART-experienced with
no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000
copies/mL and CD4+ cell count ≥100 cells/mm3, will be published on the website on Monday
10 March 2014.
4.9
zonisamide 25mg, 50mg and 100mg capsules (Zonegran®) (No: 949/14) Eisai Limited
4.9.1
The SMC advice for zonisamide (Zonegran®), as adjunctive therapy in the treatment of partial
seizures, with or without secondary generalisation, in adolescents, and children aged 6 years
and above, will be published on the website on Monday 10 March 2014.
SMC Meetings/SMC Minutes – 04 March 2014
Page 4 of 11
Scottish Medicines Consortium (SMC)
Non Submission
4.10
saxagliptin (Onglyza ®) 2.5mg & 5mg film-coated tablets (No: 958/14)
Bristol Myers Squibb / Astra Zeneca
4.10.1
The SMC advice for saxagliptin (Onglyza ®), for monotherapy in adult patients aged 18 years
and older with type 2 diabetes mellitus to improve glycaemic control inadequately controlled
by diet and exercise alone and for whom metformin is inappropriate due to contraindications
or intolerance, will be published on the website on Monday 10 March 2014.
4.11
Deferred Advice
4.11.1
teriflunomide, 14mg, film-coated tablets (Aubagio®) SMC No. (940/14)
Genzyme Ltd.
The advice for teriflunomide, 14mg, film-coated tablets (Aubagio®), from the January 2014
SMC meeting was withheld pending confirmation of product availability. However, Genzyme
confirmed that stock became available on the 4th of February 2014. Therefore, the advice
was distributed to NHS Boards/ADTCs on Friday 07 February and will be published on
Monday 10 March 2014.
4.11.2
lipegfilgrastim, 6mg, solution for injection (Lonquex®) SMC No. (908/13) Teva Pharma BV
The advice for lipegfilgrastim, 6mg, solution for injection (Lonquex®), from the October 2013
SMC meeting was withheld pending confirmation of product availability. Teva Pharma BV
have confirmed that stock is now available, Therefore, the advice will be distributed to NHS
Boards/ADTCs on Friday 07 March and will be published on Monday 07 April 2014.
4.11.3
dimethyl fumarate 120mg, 240mg gastro-resistant hard capsules (Tecfidera®)
No. (886/13) Biogen Idec Ltd
SMC
The advice for dimethyl fumarate 120mg, 240mg gastro-resistant hard capsules (Tecfidera®),
for treatment of adult patients with relapsing remitting multiple sclerosis, was withheld by
SMC in July 2013 pending confirmation of product availability. Tecfidera® is now
commercially available. Therefore, the advice will be distributed to NHS Boards/ADTCs on
Friday 07 March and will be published on Monday 07 April 2014.
4.12
Amended Advice
4.12.1
ustekinumab (Stelara®) Janssen-Cilag (No. 944/14)
In February 2014, SMC reviewed a submission for ustekinumab (Stelara), for the treatment of
active psoriatic arthritis in adult patients when the response to previous non-biological
disease-modifying anti-rheumatic drug therapy has been inadequate.
Due to comments from a comparator company, minor amendments have been made to the
‘Summary of Summary of Clinical Effectiveness’. The revised Advice will be re-issued to
NHS Boards/ADTCs on Friday 07 March, and published on Monday 10 March 2014.
4.12.2
teriflunomide (Aubagio®), Genzyme (No. 940/14)
In January 2014, SMC reviewed a submission for tereflunomide (Aubagio®), for the treatment
of adults with relapsing remitting multiple sclerosis (MS). The advice was withheld pending
SMC Meetings/SMC Minutes – 04 March 2014
Page 5 of 11
Scottish Medicines Consortium (SMC)
confirmation of product availability but was issued to NHS Boards/ADTCs on 07 February
2014.
Due to comments from a comparator company, minor amendments have been made to the
‘Summary of evidence on comparative efficacy’ and ‘Summary of Summary of Clinical
Effectiveness’. The revised Advice will be re-issued to NHS Boards/ADTCs on Friday 07
March, and published on Monday 10 March 2014.
4.12.3
afatinib (Giotrif®) Boehringer Ingelheim (No. 920/13)
In November 2013, SMC reviewed a submission, as monotherapy, for the treatment of
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR
mutation(s). The advice was withheld pending confirmation of product availability but was
issued to NHS Boards/ADTCs on 07 February 2014.
Due to comments from the submitting company, minor amendments have been made to the
‘Summary of evidence on comparative efficacy’. The revised Advice will be re-issued to NHS
Boards/ADTCs on Friday 07 March, and published on Monday 10 March 2014.
5.
Appeals Update
5.1
alogliptin, 25mg, 12.5mg, 6.25mg, film-coated tablets (Vipidia®) SMC No. (937/14) Takeda
Pharma A/S
Takeda Pharma has indicated that they will make a resubmission for alogliptin, (Vipidia®), for
adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in
combination with other glucose lowering medicinal products including insulin, when these,
together with diet and exercise, do not provide adequate glycaemic control.
6.
Patient and Public Involvement Group (PAPIG)
6.1
Verbal Update from Chair of PAPIG, John Dally on PAPIG business
Mr Dally reported the following:
•
•
•
Patient and Clinician Engagement (PACE)
Process will fit into the current SMC process and PAPIG will be involved particularly
in respect of Patient Interest Groups who will be involved in the PACE process.
Focus Groups
The first of the Scottish Health Council / PAPIG led focus groups has taken place and
further wide-ranging focus groups are being arranged.
Observers - Patient Interest Groups, please see item 1.4
7.
New Drugs Committee: Chairman’s Report
7.1
Nothing to report.
8.
Chairman’s Business
8.1
Nothing to report.
SMC Meetings/SMC Minutes – 04 March 2014
Page 6 of 11
Scottish Medicines Consortium (SMC)
9.
NDC ASSESSMENT REPORTS
FULL SUBMISSIONS
9.1
macitentan, 10mg film-coated tablets (Opsumit®)
Actelion Pharmaceuticals Limited
9.1.1
A member with a personal specific interest left the meeting for this part of the agenda.
9.1.2
The NDC Co-Vice provided an overview of the assessment, draft advice, expert comments
and tabled experts, revised data/analysis, and comments received from the company.
Detailed discussion followed and the group agreed that macitentan, (Opsumit®), should be
accepted for restricted use within NHS Scotland.
SMC No. (952/14)
Indication under review: as monotherapy or in combination, is indicated for the long-term
treatment of pulmonary arterial hypertension in adult patients of World Health Organisation
Functional Class II to III.
SMC restriction: to initiation and prescribing by specialists in the Scottish Pulmonary
Vascular Unit or similar specialists.
In a pivotal phase lll study in patients with pulmonary arterial hypertension, macitentan
significantly increased the time to a first event related to morbidity or mortality from any cause
compared with placebo. The effect was maintained for up to two years.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that
improves the cost-effectiveness of macitentan. This SMC advice is contingent upon the
continuing availability of the patient access scheme in NHS Scotland or a list price that is
equivalent or lower.
9.1.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
9.2
rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg tablet
(Eviplera®) SMC No. (951/14) Gilead Sciences Ltd.
9.2.1
Declarations of interest were recorded in relation to this product/comparator drugs. A member
with a personal specific interest left the meeting for this part of the agenda.
9.2.2
The NDC Chair provided an overview of the assessment, draft advice, expert comments,
revised data/analysis, and comments received from the company. Detailed discussion
followed and the group agreed that rilpivirine, emtricitabine, tenofovir disoproxil (as fumarate)
(Eviplera®), should be accepted for use within NHS Scotland.
Indication under review: treatment of adults infected with human immunodeficiency virus
type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside
reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load
≤100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic
resistance testing and/or historical resistance data should guide the use of Eviplera®.
Rilpivirine, emtricitabine, tenofovir (Eviplera®) maintained virological suppression in patients
switched from other antiretroviral regimens. There is no evidence of efficacy in patients
switching from other antiretroviral regimens due to virological failure.
SMC Meetings/SMC Minutes – 04 March 2014
Page 7 of 11
Scottish Medicines Consortium (SMC)
SMC issued advice in February 2012 regarding the use of Eviplera® in antiretroviral
treatment-naive adult patients. The current advice extends use to antiretroviral treatmentexperienced patients.
9.2.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
9.3
aflibercept, 40mg/mL solution for injection (Eylea®)
9.3.1
Declarations of interest were recorded in relation to this product/comparator drugs. A member
with a personal specific interest left the meeting for this part of the agenda.
9.3.2
The NDC Co-Vice Chair provided an overview of the assessment, draft advice, expert
comments, revised data/analysis, and comments received from the company. A member of
PAPIG presented a patient interest group submission from RNIB. Detailed discussion
followed and the group agreed that aflibercept, (Eylea®), should be accepted for use within
NHS Scotland.
SMC No. (954/14) Bayer
Indication under review: For adults for the treatment of visual impairment due to macular
oedema secondary to central retinal vein occlusion.
Two randomised double-masked studies demonstrated that aflibercept improved best
corrected visual acuity significantly more than sham injections in treatment-naïve adults with
macular oedema secondary to central retinal vein occlusion.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that
improves the cost-effectiveness of aflibercept. This SMC advice is contingent upon the
continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
9.3.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
9.4
fluticasone furoate/vilanterol 92/22 micrograms inhalation powder (Relvar Ellipta®)
SMC No. (953/14) GlaxoSmithKline UK
9.4.1
Declarations of interest were recorded in relation to this product/comparator drugs. A member
with a personal specific interest left the meeting for this part of the agenda.
9.4.2
The NDC Co-Vice Chair provided an overview of the assessment, draft advice, expert
comments and tabled experts, revised data/analysis, and comments received from the
company.
Detailed discussion followed and the group agreed that fluticasone
furoate/vilanterol (Relvar Ellipta®), should be accepted for restricted use within NHS
Scotland.
Indication under review: symptomatic treatment of adults with chronic obstructive
pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70%
predicted normal (post-bronchodilator) with an exacerbation history despite regular
bronchodilator therapy.
SMC restriction: in patients with severe COPD (FEV1 <50% predicted normal).
In a comparative, 12-week study there was no statistically significant difference between
fluticasone furoate/vilanterol 92/22 micrograms and another inhaled corticosteroid/long acting
SMC Meetings/SMC Minutes – 04 March 2014
Page 8 of 11
Scottish Medicines Consortium (SMC)
beta agonist combination inhaler for change from baseline trough in 24-hour weighted-mean
FEV1.
Fluticasone furoate/vilanterol is also licensed for the treatment of asthma. SMC is due to
issue advice for this indication in June 2014.
9.4.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
RESUBMISSIONS
9.5
lenalidomide, 7.5mg, 10mg, 15mg and 25mg hard capsules (Revlimid®) SMC No. (441/08)
Celgene Limited
9.5.1
Members with personal specific interests left the meeting for this part of the agenda.
9.5.2
The NDC Chair provided an overview of the assessment, draft advice, expert comments,
revised data/analysis, and comments received from the company. A member of PAPIG
presented a patient interest group submission from Myeloma UK. Detailed discussion
followed and the group agreed that lenalidomide, (Revlimid®, should be accepted for
restricted use within NHS Scotland.
Indication under review: in combination with dexamethasone, for the treatment of multiple
myeloma in adult patients who have received at least one prior therapy. (This resubmission
relates to patients who have received only one prior therapy).
SMC restriction: to use at first relapse in patients who have received prior therapy with
bortezomib in whom thalidomide has not been tolerated or is contraindicated.
Lenalidomide plus dexamethasone significantly increased the time to progression compared
with dexamethasone alone in multiple myeloma patients who had been treated with at least
one prior therapy.
SMC has previously accepted lenalidomide for use in patients who have received at least two
prior lines of therapy i.e. at second relapse. This advice now extends its use to patients at
first relapse who received bortezomib as their one prior therapy.
9.5.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
9.6
adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo®)
9.6.1
There were no declarations of interest recorded in relation to this product/comparator drugs.
9.6.2
The NDC Co-Vice Chair provided an overview of the assessment, draft advice, expert
comments, revised data/analysis, and comments received from the company. A member of
PAPIG presented a patient interest group submission from Skin Conditions Campaign
Scotland. Detailed discussion followed and the group agreed that adapalene / benzoyl
peroxide gel (Epiduo®), should be accepted for restricted use within NHS Scotland.
SMC No. (682/11) Galderma UK Ltd
Indication under review: cutaneous treatment of acne vulgaris when comedones, papules
and pustules are present.
SMC restriction: the treatment of mild to moderate facial acne when monotherapy with
SMC Meetings/SMC Minutes – 04 March 2014
Page 9 of 11
Scottish Medicines Consortium (SMC)
benzoyl peroxide or adapalene is not considered appropriate.
In 12-week studies, adapalene 0.1%/benzoyl peroxide 2.5% gel was as effective as an
alternative combination antibiotic treatment in reducing inflammatory lesions. However
adapalene 0.1%/benzoyl peroxide 2.5% gel was less well tolerated in terms of local
reactions.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that
improves the cost-effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel. This SMC
advice is contingent upon the continuing availability of the
9.6.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
ABBREVIATED SUBMISSION
9.7
azithromycin 500mg powder for solution for infusion (Zedbac®) (No. 950/14)
Aspire Pharma Limited
9.7.1
There were no declarations of interest recorded in relation to this product/comparator drugs
9.7.2
The NDC Chair provided an overview of the assessment, draft advice, revised data/analysis,
and comments received from the company. Detailed discussion followed and the group
agreed that azithromycin 500mg powder for solution for infusion (Zedbac®), should be
accepted for use within NHS Scotland.
Indication under review: the treatment of community acquired pneumonia (CAP) and pelvic
inflammatory disease (PID) due to susceptible organisms in adult patients where initial
intravenous therapy is required.
Consideration should be given to official guidance regarding the appropriate use of
antibacterial agents.
This is the first intravenous formulation of azithromycin to be made available in the UK.
The intravenous formulation is significantly more expensive than the oral preparation of
azithromycin, but it is intended only for short-term use and on the advice of local
microbiologists or specialists in infectious diseases.
9.7.3
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 07 March 2014.
10
SMC User Group Forum (UGF)
10.1
Verbal Update from the Chair of the UGF
Dr Frances Macdonald, Chair of the User Group Forum advised nothing to report and
business as usual.
10.2
The Pharmaceutical Price Regulation Scheme (PPRS)
Dr Frances Macdonald presented information on medicines pricing in the UK. The Health
Departments in the UK and the ABPI have a common interest in ensuring that safe and
effective medicines are available on reasonable terms to the NHS and in maintaining a
strong, efficient and profitable pharmaceutical industry.
The SMC members found the
SMC Meetings/SMC Minutes – 04 March 2014
Page 10 of 11
Scottish Medicines Consortium (SMC)
information very interesting.
11.
Forthcoming Submissions
11.1
A list of forthcoming submissions was tabled and noted.
12.
Area Drug & Therapeutics Committee (ADTC) Issues
12.1
Nothing to report.
13.
Any Other Business
13.1
Professor Angela Timoney, FRPharmS - Outgoing SMC Chairman
Professor Angela Timoney chaired SMC for the last time. Angela has been a member of
SMC since inception, in November 2001, and has contributed an enormous amount of
support and expertise to build the robust rapid HTA that SMC has become.
Professor Jonathan Fox, the incoming Chairman, thanked Angela for her dedication to SMC
and wished her well in her future career.
14.
Date of the Next Meeting
14.1
The date of the next meeting was confirmed as Tuesday, 01 April 2014 at 12.30 pm (lunch
from 12 noon), in the Lighthouse, 11 Mitchell Lane, Glasgow G1 3NU.
SMC Meetings/SMC Minutes – 04 March 2014
Page 11 of 11